Table 3.

Discontinuation Rate of Antihypertensive Drugs in the Comparative Trials

TrialAntihypertensive Drug Class (%)
ONTARGET (n = 25,620)252329
LIFE (n = 9193)2327
VALUE (n = 15,245)2624
ALLHAT (n = 24,309)272020
UKPDS (n = 758)2235
JMIC-B (n = 1650)95
  • ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DIU, diuretic; BB, β-blocker; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; LIFE, Losartan Intervention For Endpoint Reduction in Hypertension Study; VALUE, Valsartan Antihypertensive Long-Term Use Evaluation; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; UKPDS, United Kingdom Prospective Diabetes Study Group; JMIC-B, Japan Multicenter Investigation for Cardiovascular Diseases-B randomized trial.